查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931192

细胞疗法生物製造市场按製造模式、治疗领域、製程步骤、细胞类型和最终用户划分，全球预测（2026-2032年）

Cell Therapy Biomanufacturing Market by Manufacturing Model, Therapy Area, Process Stage, Cell Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，细胞疗法生物製造市场规模将达到 84.6 亿美元，到 2026 年将成长至 97.5 亿美元，复合年增长率为 16.46%，到 ​​2032 年将达到 246 亿美元。

关键市场统计数据
基准年 2025 84.6亿美元
预计年份：2026年 97.5亿美元
预测年份 2032 246亿美元
复合年增长率 (%) 16.46%

生物製造领域的领导者需要紧急行动起来，将实验室层级的细胞疗法进展转化为可靠、符合监管规定的生产生态系统。

细胞治疗生物製造领域正迅速成熟，融合了科学创新、程式工程和临床需求。随着开发平臺的不断演进，企业面临的挑战日益严峻，即如何将实验室规模的成功转化为可重复、合规的生产运营，以满足患者的需求。这种转变不仅仅是规模化生产的挑战；它需要重新思考製程架构、品质系统和商业模式，以协调活细胞产品的生物学复杂性与工业生产的一致性以及监管要求。

技术进步、分散式处理趋势和策略联盟如何重塑细胞疗法生产和商业化策略

细胞疗法生物製造正经历一场变革浪潮，其驱动力来自技术突破、不断变化的监管要求以及新型商业模式。自动化、封闭式系统处理和一次性技术的进步降低了人工干预和污染风险，而分析技术和数位化製程控制则实现了对关键品质属性的严格监控。同时，基因编辑、细胞工程和冷冻保存技术的创新正在拓展製造平台必须应对的治疗方法，促使人们重新评估资本投资和技术蓝图。

评估2025年关税调整对细胞疗法供应链、筹资策略和製造地的综合营运和策略影响。

预计于2025年实施或生效的关税调整，加剧了细胞疗法生物製造领域现有供应链的复杂性，其累积影响远不止于成本上涨。关键原料、一次性组件和专用设备的进口关税，即时对上游工程价格构成压力，进而影响筹资策略和库存管理政策。因此，製造商正在重新评估供应商多元化、近岸外包方案以及缓衝库存政策，以应对成本波动，同时确保供应的连续性。

详细的細項分析揭示了製造模式、治疗方法、製程阶段、最终用户和细胞类型如何驱动不同的营运重点和策略选择。

对市场细分细微差别的分析表明，生产模式、治疗领域、最终用户、製程阶段和细胞类型各自构成不同的营运和商业需求。基于生产模式，市场可细分为「异体移植」（包括现成平台和通用供体架构）和「自体移植」（涵盖从分散式处理到患者特异性工作流程）。这些差异会影响资本密集度、週期时间敏感度和品管策略。现成产品强调规模化生产和製程标准化，而病患特异性产品则需要客製化低温运输、物流和快速释放检测。

美洲、欧洲、中东和非洲以及亚太地区的製造业投资、监管多样性和供应链策略的区域观点

区域趋势在细胞治疗生物製造领域的技术采纳、监管参与和供应链设计方面发挥关键作用。美洲地区拥有强劲的转化研究动能、成熟的契约製造生态系统以及强调严格临床数据和品质系统的法规环境。这些条件促进了集中资本投资以及生物技术公司与契约製造之间的创新伙伴关係。另一方面，欧洲、中东和非洲地区（EMEA）的情况则更为复杂，各司法管辖区的监管环境存在差异，并且更加重视报销依据和真实世界数据。跨境生产合作也十分普遍，旨在利用专业知识，同时控製成本并确保合规。

开发商、合约研发生产机构 (CDMO) 和技术供应商如何协调营运整合、策略伙伴关係和平台投资以获得竞争优势

细胞治疗价值链上的各家公司正在采取差异化策略来应对复杂性并加速商业化进程。成熟的研发企业正日益将上游工程优化与下游的纯化、填充和包装能力相结合，以减少交接环节并缩短研发週期；而新兴企业则倾向于依赖策略性外包来获取专业的生产能力和合规基础设施。合约研发生产机构（CDMO）正从纯粹的交易服务提供者转型为提供製程开发专业知识、模组化生产平台和规模化生产技术的策略合作伙伴。

经营团队切实可行的策略步骤，才能让产品设计、可扩展製造和供应链韧性保持一致，以实现商业性成功？

为确保细胞疗法的供应可靠、合规且经济高效，产业领导者应优先采取一系列切实可行的措施，使科学创新与产业现实相契合。首先，将可製造性评估纳入临床前和早期临床项目，可使产品设计从研发早期阶段就与生产可行性相匹配，从而减少返工并加速向常规生产的过渡。其次，采用模组化、可扩展的製程架构，允许在不中断检验的工作流程的情况下逐步扩大产能，从而确保即使需求和产品种类发生变化，也能维持品质的连续性。

我们采用了严谨的混合调查方法，结合访谈、监管审查、供应链映射和情境分析，以检验我们的实践发现。

我们的研究途径结合了定性和定量方法，以获得可靠且检验的研究结果，这些结果反映了实际营运和策略需求。主要研究包括对研发、生产和供应部门的高阶领导进行结构化访谈，以及与监管专家和临床生产从业人员进行引导式讨论​​。这些对话让我们深入了解了实际流程的限制因素、技术采用的驱动因素，以及跨多个地点进行技术转移和验证所面临的实际挑战。

策略整合强调，整合可製造性、供应链韧性和区域监管完整性对于将细胞疗法带给患者至关重要。

总之，要将细胞疗法从实验室创新发展到可靠的患者供应，需要的不仅仅是技术突破。它还需要一套整合的营运策略，涵盖生产方法、製程成熟度、供应链韧性以及区域监管现实。那些积极将产品设计与可製造性相结合、投资模组化和自动化流程并建立策略伙伴关係的企业，将能够更有效地应对活细胞产品固有的复杂性。此外，随着行业的扩张，适应不断变化的贸易政策和区域趋势的能力将成为至关重要的竞争优势。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依製造模式分類的细胞疗法生物製造市场

  • 同种异体移植
    • 现成的模具
    • 通用捐赠平台
  • 自有住房
    • 分散式处理
    • 患者特异性工作流程

9. 按治疗领域分類的细胞疗法生物製造市场

  • 自体免疫疾病
  • 循环系统
  • 神经系统疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固态肿瘤
  • 整形外科

第十章：依製程阶段分類的细胞疗法生物製造市场

  • 冷冻保存
  • 下游工艺
    • 配方
    • 收集/净化
  • 填充和表面处理工程
  • 上游工程
    • 细胞培养扩增
    • 细胞分离

11. 依细胞类型分類的细胞疗法生物製造市场

  • 树突细胞疗法
  • 造血干细胞
  • 诱导性多功能干细胞
  • 间质干细胞
    • 脂肪衍生的
    • 骨髓来源
    • 脐带来源
  • 自然杀手细胞疗法
  • T细胞疗法
    • CAR-T
    • TCR T细胞疗法

第十二章 细胞疗法生物製造市场（按最终用户划分）

  • 学术研究机构
  • 合约开发和製造组织
  • 医院
  • 製药和生物技术公司

第十三章 细胞疗法生物製造市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 细胞疗法生物製造市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国细胞疗法生物製造市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国细胞疗法生物製造市场

第十七章：中国细胞治疗生物製造市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Asahi Kasei Corporation
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Catalent, Inc.
  • Celgene Corporation
  • Cellectis SA
  • Charles River Laboratories International, Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Gilead Sciences, Inc.
  • Hitachi Chemical Co., Ltd.
  • Intellia Therapeutics, Inc.
  • Johnson & Johnson
  • Kite Pharma
  • Lonza Group Ltd.
  • Merck KGaA
  • MilliporeSigma
  • Novartis AG
  • Precision BioSciences, Inc.
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-7B550E008DAC

The Cell Therapy Biomanufacturing Market was valued at USD 8.46 billion in 2025 and is projected to grow to USD 9.75 billion in 2026, with a CAGR of 16.46%, reaching USD 24.60 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.46 billion
Estimated Year [2026] USD 9.75 billion
Forecast Year [2032] USD 24.60 billion
CAGR (%) 16.46%

An urgent orientation for biomanufacturing leaders to transform laboratory cell therapy advances into reliable, regulatory-ready manufacturing ecosystems

The cell therapy biomanufacturing landscape is rapidly maturing at the intersection of scientific innovation, process engineering, and clinical demand. As development pipelines progress, organizations are increasingly required to convert laboratory-scale success into reproducible, compliant manufacturing operations that meet patient needs. This transition is not merely a scale-up challenge; it requires rethinking process architectures, quality systems, and commercial models to reconcile the biologic complexity of living cell products with industrial consistency and regulatory expectations.

Consequently, executives and technical leaders must align decisions across product design, supply chain configuration, and manufacturing footprint to ensure clinical agility and operational resilience. In practice, this means evaluating whether to pursue centralized, high-volume production for allogeneic formats or decentralized, patient-proximate workflows for autologous therapies. It also entails integrating automation where appropriate, strengthening cold chain capabilities, and preparing for regulatory scrutiny on critical quality attributes and release assays. By recognizing these systemic imperatives early, organizations can reduce downstream risk and accelerate the path from clinical proof-of-concept to sustainable commercial supply.

How technological advances, decentralized processing trends, and strategic partnerships are reshaping cell therapy manufacturing and commercial strategies

Cell therapy biomanufacturing is experiencing transformative shifts driven by technological breakthroughs, evolving regulatory expectations, and new commercial models. Advances in automation, closed-system processing, and single-use technologies are reducing manual intervention and contamination risk, while analytics and digital process control enable tighter monitoring of critical quality attributes. At the same time, innovations in gene editing, cell engineering, and cryopreservation are expanding the therapeutic modalities that manufacturing platforms must accommodate, prompting a re-evaluation of capital investments and technology roadmaps.

Moreover, the industry is witnessing a strategic recalibration of manufacturing models. Allogeneic approaches are incentivizing investments in scale and platform standardization to support off-the-shelf availability, whereas autologous therapies are pushing toward decentralized or hub-and-spoke models that prioritize speed and patient proximity. In parallel, partnerships between developers, contract manufacturers, and specialized suppliers are becoming more strategic and integrated, enabling end-to-end solutions that combine clinical expertise with operational capacity. These shifts are reshaping how organizations plan capacity, allocate R&D budgets, and negotiate regulatory pathways, and they require leaders to adopt flexible strategies that accommodate both current program needs and next-generation modalities.

Assessing the compound operational and strategic consequences of 2025 tariff adjustments on supply chains, procurement strategies, and manufacturing footprints in cell therapy

Tariff adjustments implemented or anticipated in 2025 have compounded existing supply chain complexities for cell therapy biomanufacturing, with cumulative effects that reach beyond simple cost increases. Import duties on critical raw materials, single-use components, and specialized equipment create immediate upstream price pressure that can influence sourcing strategies and inventory policies. Consequently, manufacturers are reassessing supplier diversity, nearshoring alternatives, and buffer stock policies to preserve continuity of supply while managing cost volatility.

In addition, tariffs have accelerated structural adjustments in procurement and manufacturing footprints. For some organizations, the tariff environment has justified investments in domestic capacity or closer regional partners to mitigate exposure to trade frictions. For others, the tariffs have driven closer collaboration with suppliers to redesign components or substitute materials where regulatory and product quality constraints allow. From a regulatory and compliance standpoint, tariff-driven reshoring can introduce new validation and regulatory notification requirements that must be anticipated early. Ultimately, the cumulative impact of tariff measures manifests as higher operational complexity, a renewed focus on supply chain resilience, and a strategic premium on flexibility in sourcing and manufacturing location decisions.

Detailed segmentation analysis revealing how manufacturing model, therapy modality, process stage, end user, and cell type drive divergent operational priorities and strategic choices

A nuanced view of market segmentation highlights how manufacturing model, therapy area, end user, process stage, and cell type each shape distinct operational and commercial imperatives. Based on manufacturing model, the market divides into allogeneic approaches, which include off-the-shelf platforms and universal donor architectures, and autologous approaches, which span decentralized processing and patient-specific workflows. These distinctions influence capital intensity, cycle time sensitivity, and quality control strategies, with off-the-shelf products favoring scale and process standardization while patient-specific products demand bespoke cold chain, logistics, and rapid release assays.

Therapy area segmentation shows diverse demands across autoimmune, cardiovascular, neurological, oncology, and orthopedic indications, with oncology further distinguished by hematologic malignancy programs and solid tumor approaches. Each therapeutic focus imposes different potency, dosing, and delivery challenges that must be reconciled with manufacturing capabilities. Based on end user, variation emerges among academic research institutes, contract development and manufacturing organizations, hospitals, and pharmaceutical and biotechnology companies; additionally, hospital settings include hospital-based processing labs and specialty treatment centers, reflecting differing regulatory supervision and throughput expectations. Process stage segmentation differentiates cryopreservation, downstream processing, fill-finish, and upstream processing, where cryopreservation comprises freeze-thaw optimization and storage, downstream processing includes formulation and harvesting purification, and upstream processing includes cell culture expansion and cell separation. Finally, cell type segmentation captures Dendritic Cell Therapy, Hematopoietic Stem Cell, Induced Pluripotent Stem Cell, Mesenchymal Stem Cell, Natural Killer Cell Therapy, and T Cell Therapy, with mesenchymal cells further defined by adipose, bone marrow, and umbilical cord sources and T cell therapy encompassing CAR T and TCR T modalities. Collectively, these intersecting segmentations create distinct value chain requirements that influence technology choices, regulatory approaches, and partnership strategies across the industry.

A regional perspective on manufacturing investment, regulatory diversity, and supply chain strategies across the Americas, Europe Middle East Africa, and Asia Pacific

Regional dynamics play a critical role in shaping technology adoption, regulatory interaction, and supply chain design for cell therapy biomanufacturing. In the Americas, there is strong momentum in translational research, an established contract manufacturing ecosystem, and a regulatory environment that emphasizes rigorous clinical data and quality systems; these conditions favor both centralized capacity investments and innovative partnerships between biotechs and contract manufacturers. In contrast, Europe, Middle East & Africa present a heterogeneous landscape where regulatory frameworks vary by jurisdiction, there is a growing emphasis on reimbursement evidence and real-world data, and cross-border manufacturing collaborations are common to leverage specialized capabilities while managing cost and compliance.

Asia-Pacific is characterized by rapidly expanding clinical activity, increasing manufacturing investment, and government-led initiatives to build domestic biomanufacturing capacity and talent. This region's focus on scaling production and building local supply chains has incentivized both multinational investment and indigenous technology development, creating new options for sourcing and regional manufacturing hubs. Across regions, differences in labor costs, regulatory timelines, and reimbursement policy mean that manufacturing strategies must be tailored to local conditions while preserving global consistency for product quality and regulatory compliance. Therefore, regional insights should inform decisions about where to locate capacity, how to structure logistics, and which partnerships to pursue for market access and operational resilience.

How developers, CDMOs, and technology suppliers are aligning operational integration, strategic partnerships, and platform investments to gain competitive advantage

Companies operating across the cell therapy value chain are adopting differentiated strategies to manage complexity and accelerate commercialization. Established developers are increasingly integrating upstream process optimization with downstream purification and fill-finish capabilities to reduce handoffs and shorten timelines, while emerging firms often rely on strategic outsourcing to access specialized capacity and compliance infrastructure. Contract development and manufacturing organizations are evolving from transactional service providers into strategic partners that contribute process development expertise, modular manufacturing platforms, and scale-up knowledge.

Equipment and consumables suppliers are also reshaping their offerings to support reproducibility and scalability, investing in closed systems, automation solutions, and analytics that facilitate consistent manufacturing across sites. Additionally, collaboration between clinical centers and manufacturing organizations is becoming more formalized, driven by the need to align clinical protocols with manufacturing constraints and to secure patient access pathways. Investors and corporate development teams are prioritizing assets and partnerships that reduce technical risk and create defensible operational advantages, such as proprietary manufacturing platforms or validated, repeatable workflows that can be transferred across geographies. This competitive environment rewards organizations that can combine technical excellence with flexible commercial models and proven regulatory execution.

Practical strategic moves executives should implement to align product design, scalable manufacturing, and supply chain resilience for commercial success

Industry leaders should prioritize a set of actionable moves that reconcile scientific innovation with industrial reality to achieve reliable, compliant, and cost-effective supply for cell therapies. First, align product design with manufacturing feasibility early in development by embedding manufacturability assessments into preclinical and early clinical programs; this reduces rework and accelerates pathway to routine production. Second, adopt modular and scalable process architectures that enable incremental capacity expansion without disrupting validated workflows, thereby maintaining quality continuity as demand and product variants evolve.

Third, strengthen supply chain resilience by diversifying suppliers for critical raw materials, qualifying regional partners for strategic redundancy, and investing in cold chain visibility and contingency planning. Fourth, pursue strategic partnerships with contract manufacturers and automation suppliers to bridge capability gaps rapidly while transferring knowledge through rigorous tech transfer protocols. Fifth, invest in analytical control strategies and digital process monitoring to enable real-time release paradigms where appropriate and to reduce release cycle time. Finally, proactively engage with regulators and payers to align on evidence generation plans that support product approval and reimbursement, thereby reducing downstream commercialization risk. Taken together, these steps create an operational foundation that supports both near-term program execution and long-term commercial resilience.

A rigorous mixed-methods research methodology integrating interviews, regulatory review, supply chain mapping, and scenario analysis to validate practical insights

The research approach combined qualitative and quantitative methods to ensure a robust, validated set of findings that reflect operational realities and strategic imperatives. Primary research included structured interviews with senior leaders across developer, manufacturing, and supplier organizations, as well as guided discussions with regulatory experts and clinical manufacturing practitioners. These engagements provided insights into real-world process constraints, technology adoption drivers, and the practicalities of tech transfer and validation across sites.

Secondary research encompassed a thorough review of peer-reviewed literature, regulatory guidance documents, white papers from industry consortia, and publicly available company disclosures to contextualize technological advances and policy shifts. Supply chain mapping identified critical raw material nodes and single-use component dependencies, while scenario analysis examined the operational impact of trade policy changes and regional manufacturing decisions. Findings were triangulated through cross-validation with subject matter experts and case studies to ensure relevance and applicability. The methodology thus blends empirical evidence with strategic scenario planning to produce insights that are actionable for senior decision-makers.

Strategic synthesis emphasizing the imperative to integrate manufacturability, supply chain resilience, and regional regulatory alignment to advance cell therapies to patients

In conclusion, advancing cell therapies from laboratory innovation to reliable patient supply requires more than technical breakthroughs; it demands integrated operational strategies that address manufacturing modality, process maturity, supply chain resilience, and regional regulatory realities. Organizations that proactively align product design with manufacturability, invest in modular and automated processes, and cultivate strategic partnerships will be better positioned to navigate the complexity inherent to living cell products. Furthermore, adapting to trade-policy shifts and regional dynamics will be a defining competency as the industry scales.

As the field continues to evolve, leaders must balance near-term execution demands with long-term platform development, ensuring that investments in capability and capacity are adaptable to successive generations of cell therapies. By following a disciplined approach that combines technical rigor, operational flexibility, and strategic engagement with regulatory and reimbursement stakeholders, organizations can reduce commercialization risk and accelerate patient access to transformative therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Biomanufacturing Market, by Manufacturing Model

  • 8.1. Allogeneic
    • 8.1.1. Off The Shelf
    • 8.1.2. Universal Donor Platform
  • 8.2. Autologous
    • 8.2.1. Decentralized Processing
    • 8.2.2. Patient Specific Workflow

9. Cell Therapy Biomanufacturing Market, by Therapy Area

  • 9.1. Autoimmune
  • 9.2. Cardiovascular
  • 9.3. Neurological
  • 9.4. Oncology
    • 9.4.1. Hematologic Malignancies
    • 9.4.2. Solid Tumors
  • 9.5. Orthopedic

10. Cell Therapy Biomanufacturing Market, by Process Stage

  • 10.1. Cryopreservation
  • 10.2. Downstream Processing
    • 10.2.1. Formulation
    • 10.2.2. Harvesting Purification
  • 10.3. Fill Finish
  • 10.4. Upstream Processing
    • 10.4.1. Cell Culture Expansion
    • 10.4.2. Cell Separation

11. Cell Therapy Biomanufacturing Market, by Cell Type

  • 11.1. Dendritic Cell Therapy
  • 11.2. Hematopoietic Stem Cell
  • 11.3. Induced Pluripotent Stem Cell
  • 11.4. Mesenchymal Stem Cell
    • 11.4.1. Adipose Derived
    • 11.4.2. Bone Marrow Derived
    • 11.4.3. Umbilical Cord Derived
  • 11.5. Natural Killer Cell Therapy
  • 11.6. T Cell Therapy
    • 11.6.1. CAR T
    • 11.6.2. TCR T

12. Cell Therapy Biomanufacturing Market, by End User

  • 12.1. Academic Research Institute
  • 12.2. Contract Development & Manufacturing Organization
  • 12.3. Hospital
  • 12.4. Pharmaceutical Biotechnology Company

13. Cell Therapy Biomanufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Therapy Biomanufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Therapy Biomanufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell Therapy Biomanufacturing Market

17. China Cell Therapy Biomanufacturing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Asahi Kasei Corporation
  • 18.6. bluebird bio, Inc.
  • 18.7. Bristol Myers Squibb Company
  • 18.8. Catalent, Inc.
  • 18.9. Celgene Corporation
  • 18.10. Cellectis S.A.
  • 18.11. Charles River Laboratories International, Inc.
  • 18.12. CRISPR Therapeutics AG
  • 18.13. Editas Medicine, Inc.
  • 18.14. FUJIFILM Diosynth Biotechnologies
  • 18.15. Gilead Sciences, Inc.
  • 18.16. Hitachi Chemical Co., Ltd.
  • 18.17. Intellia Therapeutics, Inc.
  • 18.18. Johnson & Johnson
  • 18.19. Kite Pharma
  • 18.20. Lonza Group Ltd.
  • 18.21. Merck KGaA
  • 18.22. MilliporeSigma
  • 18.23. Novartis AG
  • 18.24. Precision BioSciences, Inc.
  • 18.25. Sartorius AG
  • 18.26. Takara Bio Inc.
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 243. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 244. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 246. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 249. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 250. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 282. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 283. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 285. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 287. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 288. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 289. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 291. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 295. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 296. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO CE